Article ; Online: Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe.
BMC cancer
2021 Volume 21, Issue 1, Page(s) 854
Abstract: ... metastatic (R/M) SCCHN have a poor prognosis and substantial disease burden, including impaired ... The aim of this study was to characterize the impact of R/M SCCHN and its first-line treatment on patient ... from Europe.: Methods: This was a multicentre retrospective study of patients with R/M SCCHN in France ...
| Abstract | Background: Although current therapy for patients with early-stage squamous cell carcinoma of the head and neck (SCCHN) is potentially curative, the recurrence rate is high. Patients with recurrent or metastatic (R/M) SCCHN have a poor prognosis and substantial disease burden, including impaired health-related quality of life (HRQoL), productivity loss and indirect costs, such as need for caregiver support. The aim of this study was to characterize the impact of R/M SCCHN and its first-line treatment on patient and caregiver quality of life, daily activities and work productivity using real-world evidence from Europe. Methods: This was a multicentre retrospective study of patients with R/M SCCHN in France, Germany, Italy, Spain and the United Kingdom incorporating patient and caregiver surveys, and a physician-reported medical chart review, conducted between January and May 2019. Patients aged 18 or over with a physician confirmed diagnosis R/M SCCHN completed four validated measures of disease activity and its impact on quality of life and work productivity, while caregivers also completed questionnaire to assess the burden of providing care. Physicians provided data for clinical characteristics, patient management, testing history and treatment patterns. Results: A total of 195 medical/clinical oncologists provided data for 937, predominantly male (72%) patients, with almost half of patients aged over 65 years. The most frequently reported symptoms were fatigue (43%), weight loss (40%), pain (35%) and difficulty swallowing (32%). The EXTREME regimen was the most common first line therapy in over half of patients, who reported moderate or extreme pain/discomfort, and anxiety/depression, and problems with self-care resulting in a diminished health status compared with the general population. Only 14% were employed with high absenteeism or presenteeism, and over half of patients had a caregiver for whom the burden of care was substantial. Conclusion: Our results provide real-world insight into the multi-faceted burden associated with R/M SCCHN. The combination of poor HRQoL and the impairment in daily activities, social life and employment illustrates the wider impact of R/M SCCHN on patients and their caregivers, and highlights a need for novel 1 L treatment regimens to improve the humanistic and productivity burdens of this cancer. |
|---|---|
| MeSH term(s) | Activities of Daily Living ; Combined Modality Therapy ; Cost of Illness ; Efficiency ; Europe/epidemiology ; Female ; Humans ; Male ; Neoplasm Staging ; Prognosis ; Public Health Surveillance ; Quality of Life ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/diagnosis ; Squamous Cell Carcinoma of Head and Neck/epidemiology ; Squamous Cell Carcinoma of Head and Neck/therapy ; Treatment Outcome |
| Language | English |
| Publishing date | 2021-07-24 |
| Publishing country | England |
| Document type | Journal Article ; Multicenter Study |
| ISSN | 1471-2407 |
| ISSN (online) | 1471-2407 |
| DOI | 10.1186/s12885-021-08557-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.